Drapier J C, Lemaire G, Petit J F
Int J Immunopharmacol. 1982;4(1):21-34. doi: 10.1016/0192-0561(82)90005-4.
Two classes of immunomodulators of bacterial origin, peptidoglycan derivatives and lipopolysaccharides, are able to block in vitro the production of plasminogen activator by elicited macrophages: the release of the enzyme into the medium is inhibited and the intracellular activity reduced. In the case of peptidoglycan derivatives, high molecular weight compounds like WSA (water-soluble adjuvant) are stronger inhibitors than small molecules like MPP (muramyl pentapeptide). MDP (muramyl dipeptide) gives partial inhibition only. WSA (at 100 micrograms/ml) completely inhibits plasminogen activator production; the inhibition is reversible and specific. LPS is active at low concentrations (25-100 ng/ml). At concentrations higher than 50-100 ng/ml the action of LPS becomes irreversible and less specific. Peptidoglycan-derived immunomodulators can inhibit plasminogen activator production in the presence of polymixin B or in the case of macrophages obtained from C3H/HeJ mice; LPS is inactive under such conditions.
两类源自细菌的免疫调节剂，即肽聚糖衍生物和脂多糖，能够在体外阻断诱导巨噬细胞产生纤溶酶原激活物：酶释放到培养基中的过程受到抑制，细胞内活性降低。就肽聚糖衍生物而言，高分子量化合物如WSA（水溶性佐剂）比小分子如MPP（胞壁酰五肽）是更强的抑制剂。MDP（胞壁酰二肽）仅产生部分抑制作用。WSA（100微克/毫升）完全抑制纤溶酶原激活物的产生；这种抑制是可逆的且具有特异性。LPS在低浓度（25 - 100纳克/毫升）时具有活性。在高于50 - 100纳克/毫升的浓度下，LPS的作用变得不可逆且特异性降低。肽聚糖衍生的免疫调节剂在存在多粘菌素B的情况下或对于从C3H/HeJ小鼠获得的巨噬细胞能够抑制纤溶酶原激活物的产生；LPS在这种条件下无活性。
